Case Reports
doi: 10.1016/0041-3879(83)90035-1.
Amikacin in the treatment of pulmonary tuberculosis
- PMID: 6193623
- DOI: 10.1016/0041-3879(83)90035-1
Item in Clipboard
Case Reports
Amikacin in the treatment of pulmonary tuberculosis
Tubercle.
1983 Jun.
Abstract
Sensitivity tests on strains from 11 patients with pulmonary tuberculosis, previously treated with kanamycin and/or capreomycin, showed incomplete cross-resistance between amikacin and capreomycin but complete cross-resistance between amikacin and kanamycin. Treatment with amikacin of 4 patients with multiply resistant strains resulted in no response as assessed by sputum smears and cultures, but resistance emerged to amikacin, kanamycin and capreomycin. Amikacin has no role in the treatment of tuberculosis as it cannot be given as an alternative to kanamycin, has no advantages over it and is more expensive.
Similar articles
-
In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.Antimicrob Agents Chemother. 2018 Feb 23;62(3):e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar. Antimicrob Agents Chemother. 2018. PMID: 29311078 Free PMC article.
-
Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.J Antimicrob Chemother. 2011 Jun;66(6):1247-54. doi: 10.1093/jac/dkr109. Epub 2011 Mar 21. J Antimicrob Chemother. 2011. PMID: 21427106
-
Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis.Tubercle. 1982 Sep;63(3):201-8. doi: 10.1016/s0041-3879(82)80031-7. Tubercle. 1982. PMID: 6817487
-
High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.Antimicrob Agents Chemother. 2009 Dec;53(12):5064-8. doi: 10.1128/AAC.00851-09. Epub 2009 Sep 14. Antimicrob Agents Chemother. 2009. PMID: 19752274 Free PMC article.
-
[Cross-resistance of tubercle bacilli (a review) (III) (author's transl)].Kekkaku. 1977 Apr;52(4):171-5. Kekkaku. 1977. PMID: 69737 Review. Japanese. No abstract available.
Cited by
-
Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infections.Br Med J (Clin Res Ed). 1988 Jan 9;296(6615):111-5. doi: 10.1136/bmj.296.6615.111. Br Med J (Clin Res Ed). 1988. PMID: 2892564 Free PMC article. Review. No abstract available.
-
Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.Antimicrob Agents Chemother. 1998 May;42(5):1295-7. doi: 10.1128/AAC.42.5.1295. Antimicrob Agents Chemother. 1998. PMID: 9593173 Free PMC article.
-
Drug treatment of tuberculosis--1992.Drugs. 1992 May;43(5):651-73. doi: 10.2165/00003495-199243050-00003. Drugs. 1992. PMID: 1379145 Review.
-
Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2005 Aug;49(8):3192-7. doi: 10.1128/AAC.49.8.3192-3197.2005. Antimicrob Agents Chemother. 2005. PMID: 16048924 Free PMC article.
-
Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?Antimicrob Agents Chemother. 1997 Mar;41(3):607-10. doi: 10.1128/AAC.41.3.607. Antimicrob Agents Chemother. 1997. PMID: 9056001 Free PMC article.